Join to access to all OVN content. Join for Free

Results for 'CSRC'

Assessing cardiac safety in oncology drug development
OVN Avatar Jonathan H Seltzer MD, MBA, MA, Gary Gintant PhD, Laleh Amiri-Kordestani MD, Jack Singer MD, Luana Pesco Koplowitz MD, PhD, Javid J Moslehi MD, Ana Barac MD, PhD, Anthony F. Yu MD
Assessing cardiac safety in oncology drug development

Cardiac safety, cardiovascular, FDA, CSRC

The Cardiac Safety Research Consortium (CSRC) highlighted the importance of addressing cardiovascular (CV) adverse effects in oncology drug development during a Think Tank meeting in October 2017. With over 1,600 cancer therapies in development, the cardiovascular toxicity of cancer treatments has b…

Jun 12th • 12 mins read

Related Topics

Loading...